Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$5.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Craig C. Parker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Beta
- 0.56
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -15.31
Financials
Revenue
$5.00M-60.0%Net Income
$50.18MEBITDA
$50.18MFree Cash Flow
$-7.43MEPS (diluted)
$-0.41Shares Outstanding (diluted)
23.15M+4829.8%Operating Expenses
$15.37MCash & Debt
$102.04MReturn of Capital
$0.00Revenue by Segment (annual)
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.48M | $-242.03M | $-32.37 |
| 2024 | $10.65M | $-63.56M | $-21.67 |
| 2023 | $0.00 | $-43.04M | $-21.33 |
| 2022 | $12.50M | $-36.00M | $-15.55 |
| 2021 | $0.00 | $-52.51M | $-23.40 |
| 2020 | $0.00 | $-32.63M | $-41.12 |
| 2019 | $0.00 | $-24.36M | $-61.94 |
Valuation
SRZNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·4d ago·Negative
…he of March 2025 Private Placement for $95.1 Million SOUTH SAN FRANCISCO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the closing of the second and final tranche of its March 2025 private placement of securities.
View source ↗ - Newsglobenewswire.com·22d ago·Negative
…ed to provide approximately $95.1M in gross proceeds SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced its Investigational New Drug (IND) application for SZN-8141 has become effective, enabling the Company to advance the program i…
View source ↗ - Newsseekingalpha.com·38d ago·Positive
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·46d ago·Negative
…ZN-8141 for the Treatment of Diabetic Macular Edema SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZ…
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Surrozen to Present at Upcoming Healthcare Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences.
View source ↗
Earnings
Fri, Nov 6(in 12 days)
Consensus estimate $-1.10 per share
Typical surprise -581.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.41 vs $-1.29beat
- Wed, May 6$-11.65 vs $-1.39miss
- Mon, Mar 23$-19.13 vs $-1.29miss
- Fri, Nov 7$-8.36 vs $-1.17miss
- Fri, Aug 8$-1.14 vs $-1.23beat
- Fri, May 9$-7.43 vs $-1.09miss
Estimates and results for SRZN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SRZN officers and directors.
- Bought
- $7.8m
- Sold
- $7.2m
46 trades
7 trades
- Tcg Crossover Gp Ii, Llcsold
- Tcg Crossover Gp Ii, Llcsold
- Li Yangsold
- Williams Charles Osold
- Parker Craig Csold
- Tcg Crossover Gp Ii, Llcbought
- Tcg Crossover Gp Ii, Llcbought
- Tcg Crossover Gp Ii, Llcbought
47 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SRZN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.